Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 18/20 | 0.41 |
| ▸ | JAK3 | P52333 | 18/20 | 0.41 |
| ▸ | JAK2 | O60674 | 10/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | SYK | P43405 | 2/20 | 0.39 |
| ▸ | TYK2 | P29597 | 1/20 | 0.39 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28778614 | 0.92 | JAK1 (0.45) | JAK1JAK3JAK2CYP3A4CYP1A2 | |
| SCHEMBL28778521 | 0.90 | JAK1 (0.44) | JAK1JAK3JAK2CYP3A4CYP1A2 | |
| SCHEMBL28778734 | 0.88 | JAK1 (0.42) | JAK1JAK3JAK2CYP3A4CYP1A2 | |
| SCHEMBL28778617 | 0.85 | ROCK2 (0.42) | JAK1JAK3JAK2CYP3A4CYP1A2 | |
| SCHEMBL28778514 | 0.84 | JAK1 (0.52) | JAK1JAK3JAK2CYP3A4CYP1A2 | |
| SCHEMBL28778597 | 0.82 | JAK1 (0.44) | JAK1JAK3JAK2CYP3A4CYP1A2 | |
| SCHEMBL28778570 | 0.78 | JAK1 (0.42) | JAK1JAK3JAK2CYP3A4CYP1A2 | |
| SCHEMBL28778626 | 0.77 | JAK1 (0.41) | JAK1JAK3JAK2CYP3A4CYP1A2 | |
| SCHEMBL29610715 | 0.76 | JAK1 (0.48) | JAK1JAK3JAK2CYP3A4CYP1A2 | |
| SCHEMBL29373330 | 0.74 | JAK1 (0.51) | JAK1JAK3JAK2CYP3A4CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114698370-A | Compounds and methods for treating cytokine release syndrome | 里格尔药品股份有限公司 | 2022-07-01 | — | — | CN | disclosed |